Cotes Robert O, Goldsmith David R, Kopelovich Sarah L, Lally Cathy A, Druss Benjamin G
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 80 Jesse Hill Jr Dr SE, Atlanta, GA, 30303, USA.
Division of Public Behavioral Health & Justice Policy, Department of Psychiatry & Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA.
Community Ment Health J. 2018 Aug;54(6):699-706. doi: 10.1007/s10597-017-0183-y. Epub 2017 Nov 10.
Antipsychotic polypharmacy (APP) is a common strategy despite guidelines advising against this practice. This article seeks to quantify the prevalence and correlates of APP using Medicaid Analytic eXtract files from 2003 to 2004. Nineteen percent of Medicaid recipients who received an antipsychotic were treated with APP. Individuals who received APP were more likely to be white, male, disabled, between the ages of 18-29, diagnosed with a psychotic disorder, and diagnosed with a higher number of psychiatric conditions. Geographic variation in APP rates was also observed. Quality improvement initiatives may help reduce APP for medically vulnerable patients.
尽管有指南不建议采用这种做法，但抗精神病药物联合治疗（APP）仍是一种常见的策略。本文旨在利用2003年至2004年的医疗补助分析提取文件，对APP的患病率及其相关因素进行量化。在接受抗精神病药物治疗的医疗补助领取者中，19%接受了APP治疗。接受APP治疗的个体更有可能是白人、男性、残疾人士，年龄在18至29岁之间，被诊断患有精神障碍，且被诊断出患有更多的精神疾病。APP发生率的地理差异也被观察到。质量改进措施可能有助于减少医疗脆弱患者的APP使用情况。
